SCHEMBL6677958

SCHEMBL6677958

Cn1c2c(c(=O)n(Cc3ccccc3)c1=O)CC(C(=O)O)CS2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.44
PKM P14618 2/20 0.44
RAB9A P51151 1/20 0.44
MAPK1 P28482 2/20 0.42
MAPT P10636 5/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 3/20 0.41
HPGD P15428 2/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 5/20 0.41
POLB P06746 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
LGMN Q99538 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2B P29275 1/20 0.40
HIF1A Q16665 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680997 0.85 S1PR1 (0.38) RAB9ALMNAGAATSHRALDH1A1
SCHEMBL6684343 0.81 MAPT (0.41) SMN1; SMN2MAPTMEN1KMT2ATSHR
SCHEMBL6682663 0.80 PKM (0.47) SMN1; SMN2PKMMAPTKMT2ALMNA
SCHEMBL6662842 0.78 SMN1; SMN2 (0.45) SMN1; SMN2PKMRAB9AMAPK1MAPT
SCHEMBL7061142 0.76 SMN1; SMN2 (0.43) SMN1; SMN2PKMRAB9AMAPTMEN1
SCHEMBL6679185 0.69 SMN1; SMN2 (0.45) SMN1; SMN2PKMRAB9AMAPK1MAPT
SCHEMBL3940708 0.66 HPGD (0.64) SMN1; SMN2PKMRAB9AMEN1KMT2A
SCHEMBL6681696 0.65 CLPP (0.39) RAB9ALMNAGAATSHRALDH1A1
SCHEMBL6683575 0.64 GAA (0.46) SMN1; SMN2PKMRAB9AMEN1KMT2A
SCHEMBL6679516 0.63 CLPP (0.33) SMN1; SMN2PKMRAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US claimed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed
WO-2004014921-A1 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 SMN1; SMN2 682/4885PKM 2081/4885RAB9A 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.